Personal Track Record
This is not an investment model
- It is a record of a member’s personal broker account as reported to Covestor
- It cannot be mirrored
Sep 27, 2010
tapebeat - View Profile
Personal Track Record
| Inception date | June 10, 2009 |
| Long/Short | Long only |
| Cap bias | Micro cap |
| Holding Period | Short term |
Performance and Risk
Performance Summary (as at end of February 09, 2012)
| Inception June 10, 2009 | Member | S&P 500 |
|---|---|---|
| Month to date (%) | 0.00 | 4.41 |
| 3 month (%) | 0.00 | 4.76 |
| 1 year (%) | -96.15 | 2.09 |
| Annualized since inception (%) | -18.99 | 0.68 |
| Since inception (%) | -42.72 | n/a |
| Sharpe (annualized) | -0.09 | 0.01 |
| % of positive months | 40.63 | 60.81 |
Past performance is not indicative of future performance
Commentary - Latest Posts
-
The Risks and Rewards of Javelin Pharmaceuticals, Inc. May 24, 2010
Shares of the Javelin Pharmaceuticals Inc (AMEX: JAV) plunged 30% to close at $1.26 after the company announced that Therabel Pharma UK Limited ("Therabel"), a subsidiary of Therabel Pharma N.V. and Javelin's licensee of commercial rights to Dyloject™ (diclofenac sodium) in the European Union recently informed Javelin and publicly announced that it is withdrawing all batches of Dyloject (diclofenac 75mg/2ml) from the UK market with a Drug Alert Class 2 Medicines Recall.
As per......
-
Nutra Pharma's Cobroxin Drug is Finally Showing Reward - Conference Scheduled April 25, 2010
Nutra Pharma's (OTC: NPHC) hard work on its Cobroxin drug is finally paying big reward dividends now that its R&D is completed, and its sales began in October of 2009. Cobroxin is the first non-prescription drug approved by the FDA to treat stage 2 (severe) chronic pain. It is a non-addictive cobra venom derivative that has received positive initial feedback, and its sales are increasing rapidly. Current company headlines constantly portray more and more marketing...... -
DCTH Shares are up on positive Phase 3 results and APPY is up as well April 22, 2010
Today on Market Summary Updates:
DCTH: Shares of Delcath Systems, Inc. (DCTH), traded on a huge volume and were up 30% in the pre-market to close the day at $12.93(19% up), after the company announced that its Phase III National Cancer Institute (NCI)-led multi-center clinical trial has successfully met the study's primary endpoint of extended hepatic progression-free survival in patients suffering from melanoma metastases in the liver.TapeBeat profiled DCTH on Monday, 29 March......
-
The Lucky Gainers For This Thursday April 08, 2010
Andes Gold Corp. (OTC:AGCZ) has jumped in the price by gaining 0.05 cents or 156% in the mid-day. The jump was based on the news that "Gold Summary Production Up 85%."
Quoting the press release from the Andes Gold Corp, "The company is pleased to announce that its production numbers are up over the January and February production period with year over year sales topping $1.13 million USD to the end of February 2010."
"The company's focus has been to build from our solid base......
- Job Title Behavioral Analysts
- Industry Education Management
- Expertise 5-10 years
- Education Graduate level
- Qualifications BCABA
- Year of Birth 1957
- Country United States
- State Florida
Follow investment models for free
Start FREE Trial - Create Mirroring AccountImportant Information
- Past performance is no guarantee of future results.
- Performance of a Personal Track Record is calculated by Covestor on a daily time-weighted basis of equity positions in the account provided by the member. It is exclusive of any commissions, fees, dividends, earnings distributions, and cash in the portfolio.
- Month to Date returns and Since Inception returns are revised daily. All other returns (month, 3 month, year to date, et al) are calculated as of the most recent month end date.
- All graph data is as of the end of day for the referenced period, unless otherwise specified.
- Benchmark returns have been calculated by Covestor using a time-weighted calculation of daily index valuations and do not include cash, dividends and earnings distributions, or transaction costs. More
- All Personal Track Record information including personal data, profiles, strategies, commentary, and historical results outside of Covestor has been provided by the Member. Covestor makes no representation or warranty of its accuracy, completeness or relevance and it does not represent the opinions of Covestor.